http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Diphoton signal of the light Higgs boson in natural NMSSM
Cao, Junjie,Guo, Xiaofei,He, Yangle,Wu, Peiwen,Zhang, Yang American Physical Society 2017 Physical review. D Vol.95 No.11
<P>The natural Next-to-Minimal Supersymmetric Standard Model (nNMSSM) is featured by predicting one CP-even Higgs boson satisfying m(h1) less than or similar to 120 GeV and Higgsinos lighter than about 300 GeV, and consequently, the cross section for dark matter (DM)-nucleon scattering in this scenario is usually quite large. We study the diphoton signal of the light Higgs boson in nNMSSM by considering the tight constraints from the latest LUX and PandaX-II experiments, and we conclude that the optimal value of the signal rate at 8 TeV LHC is greatly reduced in comparison with earlier predictions. For example, previous studies indicated that the rate may exceed 120 fb for m(h1) similar or equal to 80 GeV, while it is at most 25 fb if the lightest neutralino in the scenario is fully responsible for the measured DM relic density. We also investigate the case of m(h1) similar or equal to 98 GeV, which is hinted by the excesses of the large electron proton collider analysis on Z (b) over bar b signal and the compact muon solenoid analysis on the diphoton signal. We conclude that nNMSSM can simultaneously explain the excesses at the 1 sigma level without violating any known constraints.</P>
Scalar dark matter interpretation of the DAMPE data with U(1) gauge interactions
Cao, Junjie,Feng, Lei,Guo, Xiaofei,Shang, Liangliang,Wang, Fei,Wu, Peiwen American Physical Society 2018 Physical review. D Vol.97 No.9
<P>Recently, the Dark Matter Particle Explorer (DAMPE) experiment released the new measurement of the total cosmic e(+) e(-) flux between 25 GeV and 4.6 TeV, which indicates a spectral softening at around 0.9 TeV and a tentative peak at around 1.4 TeV. We utilize a scalar dark matter (DM) model to explain the DAMPE peak by XX -> Z'Z' -> l (l) over barl'(l) over bar 'l with an additional anomaly-free gauged U (l) family symmetry, in which X, Z'and l((')) denote, respectively, the scalar DM, the new gauge boson, and l((')) = e, mu, tau, with m(x) similar to m(z)' similar to 2 x 1.5 (TeV). We first illustrate that the minimal framework Gsm X U(l)(Y') with the above mass choices can explain the DAMPE excess, which, however, be excluded by LHC constraints from the Z' searches. Then, we study a nonminimal framework G(SM) X U(l)(Y') x U(i)(Y') in which U(l)(Y') mixes with U(l)(Y'). We show that such a framework can interpret the DAMPE data and at the same time survive all other constraints including the DM relic abundance, DM direct detection, and collider bounds. We also investigate the predicted e(+) e(-) spectrum in this framework and find that the mass splitting Delta m = m(x) - m(z') should be less than about 17 GeV to produce the peaklike structure.</P>
Jeong Heo,Yoon Jun Kim,Sung Wook Lee,Youn-Jae Lee,Ki Tae Yoon,Kwan Soo Byun,Yong Jin Jung,Won Young Tak,Sook-Hyang Jeong,Kyung Min Kwon,Vithika Suri,Peiwen Wu,Byoung Kuk Jang,Byung Seok Lee,Ju-Yeon Ch 대한내과학회 2023 The Korean Journal of Internal Medicine Vol.38 No.4
Background/Aims: Despite the availability of direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection in Korea, need remains for pangenotypic regimens that can be used in the presence of hepatic impairment, comorbidities, or prior treatment failure. We investigated the efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for 12 weeks in HCV-infected Korean adults. Methods: This Phase 3b, multicenter, open-label study included 2 cohorts. In Cohort 1, participants with HCV genotype 1 or 2 and who were treatment-naive or treatment-experienced with interferon-based treatments, received sofosbuvir–velpatasvir 400/100 mg/day. In Cohort 2, HCV genotype 1 infected individuals who previously received an NS5A inhibitor-containing regimen ≥ 4 weeks received sofosbuvir–velpatasvir–voxilaprevir 400/100/100 mg/day. Decompensated cirrhosis was an exclusion criterion. The primary endpoint was SVR12, defined as HCV RNA < 15 IU/mL 12 weeks following treatment. Results: Of 53 participants receiving sofosbuvir–velpatasvir, 52 (98.1%) achieved SVR12. The single participant who did not achieve SVR12 experienced an asymptomatic Grade 3 ASL/ALT elevation on day 15 and discontinued treatment. The event resolved without intervention. All 33 participants (100%) treated with sofosbuvir–velpatasvir–voxilaprevir achieved SVR 12. Overall, sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir were safe and well tolerated. Three participants (5.6%) in Cohort 1 and 1 participant (3.0%) in Cohort 2 had serious adverse events, but none were considered treatment-related. No deaths or grade 4 laboratory abnormalities were reported. Conclusions: Treatment with sofosbuvir–velpatasvir or sofosbuvir–velpatasvir–voxilaprevir was safe and resulted in high SVR12 rates in Korean HCV patients.